Results 171 to 180 of about 185,181 (328)

Wound, pressure ulcer, and burn guidelines (2023)―4: Guidelines for the management of connective tissue disease/vasculitis‐associated skin ulcers, third edition

The Journal of Dermatology, EarlyView.
Yoshihide Asano, Jun Asai, Takayuki Ishii, Yohei Iwata, Masanari Kodera, Chie Miyabe, Akihiko Uchiyama, Youichi Ogawa, Ken Okamura, Mari Kishibe, Yuta Koike, Yorihisa Kotobuki, Noriki Fujimoto, Takuya Miyagi, Yukie Yamaguchi, Ayumi Yoshizaki, Reiko Omori, Takeshi Nakanishi, Hiroshi Fujiwara, Takeo Maekawa, Sei‐ichiro Motegi, Yuichiro Yoshino, Minoru Hasegawa, Manabu Fujimoto, Takao Tachibana, Wound, Pressure Ulcer, and Burn Guidelines Drafting Committee (connective tissue disease/vasculitis group)   +27 more
wiley   +1 more source

Apixaban in patients with nonvalvular atrial fibrillation, heart failure and low body weight: A report from a global federated research dataset

European Journal of Clinical Investigation, Volume 55, Issue 5, May 2025.
In a cohort of 155,152 patients with atrial fibrillation, heart failure and low body weight, patients weighting <60 kg faced a higher risk of adverse events compared to those in the reference BW (60–100 kg), regardless of treatment. Apixaban demonstrated a lower risk of ischaemic stroke/systemic embolism, bleedings (including intracranial hemorrhage ...
Luca Monzo, Guillaume Baudry, Gema Hernandez, Olivier Denquin, Gianluigi Savarese, Gregory Y. H. Lip, Nicolas Girerd   +6 more
wiley   +1 more source

Economic burden of adverse drug reactions and potential for pharmacogenomic testing in Singaporean adults. [PDF]

, 2019
Adverse drug reactions (ADRs) contribute to hospitalization but data on its economic burden is scant. Pre-emptive pharmacogenetic (PGx) testing can potentially reduce ADRs and its associated costs.
Brunham, Liam R, Chan, Alexandre, Chan, Sze Ling, Ng, Hong Yen, Sung, Cynthia, Wee, Hwee-Lin, Winther, Michael D   +6 more
core   +1 more source

Warfarin brands [PDF]

Australian Prescriber, 2015
Linda Graudins, Fiona Chen, Ingrid Hopper, Philip A Tideman, Rosy Tirimacco, Andrew St John, Gregory W Roberts   +6 more
openaire   +2 more sources

Recombinant Activated Factor VIIa Combined With Tranexamic Acid Control Haemostasis in Patients With Severe Factor XI Deficiency Undergoing Urological Procedures

Haemophilia, EarlyView.
ABSTRACT Introduction Patients with severe Factor XI deficiency face unique challenges during urological procedures due to an elevated risk of bleeding, balanced against the use of tranexamic acid (TXA), which may form blood clots. Given the limitations associated with plasma‐based treatment, there have been reports of successful and safe off‐label use
Neta Sternbach, Yaron Ehrlich, Anfisa Stenevsky, Daniel Saidian, Darawsha Abd Elhalim, Jack Baniel, Pia Raanani, Galia Spectre   +7 more
wiley   +1 more source

Effectiveness and safety of antithrombin for treatment of portal vein thrombosis: Nationwide prospective surveillance of 4 years of clinical experience in Japan

Hepatology Research, EarlyView.
Abstract Aim Antithrombin (AT), a plasma protein with anticoagulant properties, has a long‐standing medical history, primarily for treatment of congenital AT deficiency. Accumulated clinical experiences suggest AT is a potential anticoagulant for thrombotic diseases. This study aimed to clarify the effectiveness, safety, and clinical significance of AT
Shoichi Matsutani, Makoto Arakawa, Susumu Nakano   +2 more
wiley   +1 more source

Activated Protein C Resistance Testing: An Update From Australasia/Asia‐Pacific

International Journal of Laboratory Hematology, EarlyView.
ABSTRACT Introduction Activated protein C resistance (APCR) represents a risk factor for thrombosis and is usually due to factor V Leiden (FVL). Clinicians may order either test (i.e., APCR or FVL) to help assess ‘thrombophilia’ in patients who present with thrombosis. APCR testing is usually achieved using clot‐based assays, whereas FVL is assessed by
Emmanuel J. Favaloro, Sandya Arunachalam, Elysse Dean, Mahzuza Salwa, Monica Ahuja, Lynne Connelly, Kent Chapman, Ronny Vong, Leonardo Pasalic   +8 more
wiley   +1 more source

Bound to bleed: How altered albumin binding may dictate warfarin treatment outcome

International Journal of Cardiology: Heart & Vasculature, 2019
Although non-vitamin-K anticoagulants are now the preferred option for stroke prevention in atrial fibrillation (AF), warfarin is still used in a significant number of patients.
Anke C. Fender, Dobromir Dobrev
doaj  

Dicoumarol and warfarin [PDF]

Heart, 1991
openaire   +2 more sources

Measuring Direct Oral Anticoagulant (DOAC) Levels: Applications, Limitations, and Future Directions

International Journal of Laboratory Hematology, EarlyView.
ABSTRACT Introduction There are important challenges with the measurement and interpretation of direct oral anticoagulant (DOAC) anticoagulant effect including a lack of therapeutic ranges, inaccuracy of routinely available coagulation assays, lack of established thresholds for clinically significant effect, and uncertainty about how to apply the ...
Siraj Mithoowani, Chee Wee Tan, Deborah M. Siegal   +2 more
wiley   +1 more source